Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumithra J Mandrekar

Showing results (61-70 of 157) with videos related to

Pageof 16
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 9, 2018
Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical ConsiderationsJennifer Le-Rademacher, Suzanne Dahlberg, J Jack Lee, et al.
JAMA Oncology|June 22, 2023
Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical TrialsShauna L Hillman, Aminah Jatoi, Carrie A Strand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouseSumithra J Mandrekar, Ming-Wen An, Jeffrey Meyers, et al.
Journal of Biopharmaceutical Statistics|July 12, 2023
Statistical Considerations and Software for Designing Sequential, Multiple Assignment, Randomized Trials (SMART) with a Survival Final EndpointSasha Kravets, Amy S Ruppert, Sawyer B Jacobson, et al.
Cancer|January 11, 2007
A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trialsMashele M Huschka, Sumithra J Mandrekar, Paul L Schaefer, et al.
Journal of Patient Experience|June 27, 2022
Succinct Cancer Clinical Trial Consent Forms in Rural Patients With Cancer: A Secondary Analysis of a Randomized, Double-Blinded studyJana Wieland, Daniel Satele, Yahya Almodallal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2020
Guidelines for Statistical Reporting in Medical JournalsFang-Shu Ou, Jennifer G Le-Rademacher, Karla V Ballman, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|May 10, 2020
Understanding Verbosity: Funding Source and the Length of Consent Forms for Cancer Clinical TrialsQuyen Duong, Sumithra J Mandrekar, Stacey J Winham, et al.
Contemporary Clinical Trials Communications|December 25, 2019
Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trialsMing-Wen An, Jun Tang, Axel Grothey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling MethodsMing-Wen An, Yu Han, Jeffrey P Meyers, et al.
Pageof 16

Showing results (61-70 of 157) with videos related to

Sort By:
Pageof 16
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 9, 2018
Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical ConsiderationsJennifer Le-Rademacher, Suzanne Dahlberg, J Jack Lee, et al.
JAMA Oncology|June 22, 2023
Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical TrialsShauna L Hillman, Aminah Jatoi, Carrie A Strand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouseSumithra J Mandrekar, Ming-Wen An, Jeffrey Meyers, et al.
Journal of Biopharmaceutical Statistics|July 12, 2023
Statistical Considerations and Software for Designing Sequential, Multiple Assignment, Randomized Trials (SMART) with a Survival Final EndpointSasha Kravets, Amy S Ruppert, Sawyer B Jacobson, et al.
Cancer|January 11, 2007
A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trialsMashele M Huschka, Sumithra J Mandrekar, Paul L Schaefer, et al.
Journal of Patient Experience|June 27, 2022
Succinct Cancer Clinical Trial Consent Forms in Rural Patients With Cancer: A Secondary Analysis of a Randomized, Double-Blinded studyJana Wieland, Daniel Satele, Yahya Almodallal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2020
Guidelines for Statistical Reporting in Medical JournalsFang-Shu Ou, Jennifer G Le-Rademacher, Karla V Ballman, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|May 10, 2020
Understanding Verbosity: Funding Source and the Length of Consent Forms for Cancer Clinical TrialsQuyen Duong, Sumithra J Mandrekar, Stacey J Winham, et al.
Contemporary Clinical Trials Communications|December 25, 2019
Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trialsMing-Wen An, Jun Tang, Axel Grothey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling MethodsMing-Wen An, Yu Han, Jeffrey P Meyers, et al.
Pageof 16